The chemokine receptor CX3CR1 is directly involved in the arrest of breast cancer cells to the skeleton

Breast Cancer Research

Volumn 13, Issue 5, 2011, Pages

  Jamieson Gladney, Whitney L ^a,b   Zhang, Yun ^a   Fong, Alan M ^c   Meucci, Olimpia ^a   Fatatis, Alessandro ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CX3CR1; COMPLEMENTARY DNA; FRACTALKINE; CHEMOKINE RECEPTOR; CX3CL1 PROTEIN, MOUSE; CX3CR1 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BONE METASTASIS; BREAST CANCER; CANCER CELL; CELL ADHESION; CLINICAL ASSESSMENT; CONTROLLED STUDY; ENDOTHELIUM; FEMALE; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MOUSE; MUTANT; NONHUMAN; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN INTERACTION; STROMA CELL; TISSUE MICROARRAY; TRANSGENIC MOUSE; ANIMAL; BAGG ALBINO MOUSE; BONE TUMOR; BREAST TUMOR; CYTOLOGY; GENETICS; METABOLISM; METASTASIS; MUTATION; PATHOLOGY;

ANIMALS; BONE MARROW CELLS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL ADHESION; CHEMOKINE CX3CL1; ENDOTHELIUM; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; MICE, TRANSGENIC; MUTATION; RECEPTORS, CHEMOKINE; STROMAL CELLS;

EID: 80054695444     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3016     Document Type: Article

References (33)

1. Hortobagyi GN, Esserman L, Buchholz TA. Neoplasms of the breast. Holland-Frei Cancer Medicine 2006, 1584-1643. Shelton, CT: People's Medical Publishing House-USA, Hong WK, Bast RC, Hait W, Kufe DW, Holland JF, Pollock RE, Weichselbaum RR.
2. Lu J, Steeg P, Price JE, Krishnamurthy S, Mani SA, Reuben J, Cristofanilli M, Dontu G, Bidaut L, Valero V, Hortobagyi GN, Yu D. Breast cancer metastasis: challenges and opportunities. Cancer Res 2009, 69:4951-4953. 10.1158/0008-5472.CAN-09-0099, 19470768.
3. Bussard K, Gay C, Mastro A. The bone microenvironment in metastasis; what is special about bone?. Cancer Metastasis Rev 2008, 27:41-55. 10.1007/s10555-007-9109-4, 18071636.
4. Coleman RE. Skeletal complications of malignancy. Cancer 1997, 80:1588-1594. 10.1002/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G, 9362426.
5. Hüsemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmüller G, Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68. 10.1016/j.ccr.2007.12.003, 18167340.
6. Aguirre-Ghiso J. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007, 7:834-846. 10.1038/nrc2256, 2519109, 17957189.
7. Sigal-Zafrani B, Lewis JS, Clough KB, Vincent-Salomon A, Fourquet A, Meunier M, Falcou MC, Sastre-Garau X, . Group ICBS Histological margin assessment for breast ductal carcinoma in situ: precision and implications. Mod Pathol 2004, 17:81-88. 10.1038/modpathol.3800019, 14657957, Group ICBS.
8. Meirovitz A, Rennert HS, Peretz T, Salmon A, Rennert G. The margins effect: residual tumor after breast conserving surgery. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 2007, 25:11045.
9. Stuelten CH, Barbul A, Busch JI, Sutton E, Katz R, Sato M, Wakefield LM, Roberts AB, Niederhuber JE. Acute wounds accelerate tumorigenesis by a T cell-dependent mechanism. Cancer Res 2008, 68:7278-7282. 10.1158/0008-5472.CAN-08-1842, 2766858, 18794114.
10. Lehr JE, Pienta KJ. Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst 1998, 90:118-123. 10.1093/jnci/90.2.118, 9450571.
11. Scott L, Clarke N, George N, Shanks J, Testa N, Lang S. Interactions of human prostatic epithelial cells with bone marrow endothelium: binding and invasion. Br J Cancer 2001, 84:1417. 10.1054/bjoc.2001.1804, 2363632, 11355957.
12. Glinskii O, Huxley V, Glinsky G, Pienta K, Raz A, Glinsky V. Mechanical entrapment is insufficient and intercellular adhesion is essential for metastatic cell arrest in distant organs. Neoplasia 2005, 7:522-527. 10.1593/neo.04646, 1501167, 15967104.
13. Liotta LA. An attractive force in metastasis. Nature 2001, 410:24-25. 10.1038/35065180, 11242022.
14. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010, 21:27-39. 10.1016/j.cytogfr.2009.11.007, 20004131.
15. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ. A new class of membrane-bound chemokine with a CX3C motif. Nature 1997, 385:640-644. 10.1038/385640a0, 9024663.
16. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem 1999, 274:10053-10058. 10.1074/jbc.274.15.10053, 10187784.
17. Imai T, Hieshima K, Haskell C, Baba M, Nagira M, Nishimura M, Kakizaki M, Takagi S, Nomiyama H, Schall TJ, Yoshie O. Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1997, 91:521-530. 10.1016/S0092-8674(00)80438-9, 9390561.
18. Goda S, Imai T, Yoshie O, Yoneda O, Inoue H, Nagano Y, Okazaki T, Imai H, Bloom E, Domae N. CX3C-chemokine, fractalkine-enhanced adhesion of THP-1 cells to endothelial cells through integrin-dependent and-independent mechanisms. J Immunol 2000, 164:4313.
19. Shulby SA, Dolloff N, Stearns M, Meucci O, Fatatis A. CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells. Cancer Res 2004, 64:4693-4698. 10.1158/0008-5472.CAN-03-3437, 15256432.
20. Jamieson WL, Shimizu S, D'Ambrosio JA, Meucci O, Fatatis A. CX3CR1 is expressed by prostate epithelial cells and androgens regulate the levels of CX3CL1/fractalkine in the bone marrow: potential role in prostate cancer bone tropism. Cancer Res 2008, 68:1715-1722. 10.1158/0008-5472.CAN-07-1315, 2669735, 18339851.
21. Chitilian HV, Laufer TM, Stenger K, Shea S, Auchincloss H. The strength of cell-mediated xenograft rejection in the mouse is due to the CD4+ indirect response. Xenotransplantation 1998, 5:93-98. 10.1111/j.1399-3089.1998.tb00014.x, 9507739.
22. Bosma GC, Custer RP, Bosma MJ. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301:527-530. 10.1038/301527a0, 6823332.
23. Russell M, Jamieson W, Dolloff N, Fatatis A. The alpha-receptor for platelet-derived growth factor as a target for antibody-mediated inhibition of skeletal metastases from prostate cancer cells. Oncogene 2009, 28:412-421. 10.1038/onc.2008.390, 18850002.
24. Kang Y, Siegel PM, Shu W, Drobnjak M, Kakonen SM, Cordón-Cardo C, Guise T, Massagué J. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003, 3:537-549. 10.1016/S1535-6108(03)00132-6, 12842083.
25. van der Pluijm G, Que I, Sijmons B, Buijs JT, Löwik CW, Wetterwald A, Thalmann GN, Papapoulos SE, Cecchini MG. Interference with the microenvironmental support impairs the de novo formation of bone metastases in vivo. Cancer Res 2005, 65:7682-7690.
26. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239. 10.1016/j.ccr.2009.01.021, 19249681.
27. Dolloff N, Russell MR, Loizos N, Fatatis A. Human bone marrow activates the Akt pathway in metastatic prostate cells through transactivation of the alpha-platelet-derived growth factor receptor. Cancer Res 2007, 67:555-562. 10.1158/0008-5472.CAN-06-2593, 17234763.
28. Russell MR, Liu Q, Lei H, Kazlauskas A, Fatatis A. The alpha-receptor for platelet-derived growth factor confers bone-metastatic potential to prostate cancer cells by ligand- and dimerization-independent mechanisms. Cancer Res 2010, 70:4195-4203. 10.1158/0008-5472.CAN-09-4712, 2875778, 20442296.
29. Russell MR, Liu Q, Fatatis A. Targeting the {alpha} receptor for platelet-derived growth factor as a primary or combination therapy in a preclinical model of prostate cancer skeletal metastasis. Clin Cancer Res 2010, 16:5002-5010. 10.1158/1078-0432.CCR-10-1863, 20813817, 20813817.
30. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM, Vassileva G, Lira SA. Generation and analysis of mice lacking the chemokine fractalkine. Mol Cell Biol 2001, 21:3159-3165. 10.1128/MCB.21.9.3159-3165.2001, 86945, 11287620.
31. Fong AM, Alam SM, Imai T, Haribabu B, Patel DD. CX3CR1 tyrosine sulfation enhances fractalkine-induced cell adhesion. J Biol Chem 2002, 277:19418-19423. 10.1074/jbc.M201396200, 11909868.
32. Chen Y, Green SR, Almazan F, Quehenberger O. The amino terminus and the third extracellular loop of CX3CR1 contain determinants critical for distinct receptor functions. Mol Pharmacol 2006, 69:857-865.
33. Garin A, Tarantino N, Faure S, Daoudi M, Lécureuil C, Bourdais A, Debré P, Deterre P, Combadière C. Two novel fully functional isoforms of CX3CR1 are potent HIV coreceptors. J Immunol 2003, 171:5305-5312.